Morgan Stanley Reiterates Biomarin Stock Rating... - Aug 31

The Story

Morgan Stanley has reiterated its rating on BioMarin Pharmaceutical, citing a settlement-based valuation framework and a set of numerical measures tied to that view. The report references figures including 28.03%, 15.17%, 0.17%, 0% and $776, keeping analysts focused on settlement developments that could alter the stock's implied value for $BMRN.

Why It Matters For Your Portfolio

• The Morgan Stanley note lists 28.03% and 15.17% among its key figures, data points investors will use to size potential upside and downside in valuation models, which could affect portfolio allocation to $BMRN.
• The report also cites 0.17% and 0% figures, suggesting limited short-term sensitivity in the firm’s scenario work, which may temper volatility expectations for the stock in the near term.
• A $776 figure appears in the analysis, a valuation input that may influence per-share math and how traders price settlement scenarios into $BMRN.
• Recent analyst activity indicates Wall Street is paying attention, and upcoming catalysts tied to the settlement and other events could move the stock quickly, altering risk profiles for growth and event-driven investors.

The Trade

If you follow event-driven or growth names, keep watching settlement developments and further analyst commentary, since Morgan Stanley has kept $BMRN on its radar. For traders, monitor momentum around any settlement announcements and changes to the figures cited, including 28.03%, 15.17% and the $776 input. Income investors may find the update less relevant given the note’s focus on valuation scenarios rather than cash returns.